Expect near-term selling pressure from the dilutive offering and potential overhang from the 2.1M purchase warrants exercisable at $2.27 starting November 2026. Monitor for any subsequent 8-K filings detailing the closing and any updates on the withZeta.ai spin-off, which could provide a partial offset if it attracts dedicated funding. The going-concern risk and need for further capital suggest continued volatility.
Price Chart
Executive Summary
Lantern Pharma is conducting a dilutive public offering of 1,454,175 shares of common stock at $2.06 per share, plus 681,748 pre-funded warrants at $2.0599 each, alongside a concurrent private placement of 2,135,923 purchase warrants exercisable at $2.27. The company expects net proceeds of approximately $3.94 million for working capital, extending its cash runway to mid-Q1 2027, but this comes at the cost of immediate 19% dilution to existing shareholders and significant future overhang from the purchase warrants. The filing also discloses a going-concern risk and the need for substantial additional funding.
Key Facts
- Offering 1,454,175 shares of common stock at $2.06 per share and 681,748 pre-funded warrants at $2.0599 each.
- Concurrent private placement of 2,135,923 purchase warrants exercisable at $2.27 per share, exercisable from 6-month anniversary for 5 years.
- Net proceeds estimated at ~$3.94 million after placement agent fees and expenses.
- Immediate dilution of $1.28 per share to new investors; net tangible book value increases from $0.58 to $0.78 per share post-offering.
- As of Dec 31, 2025, total assets ~$11.04M, working capital ~$6.3M, cash and equivalents ~$10.1M.
- Auditor's report includes going-concern explanatory paragraph; company expects to need additional financing.
- Cash runway extended to approximately mid-Q1 2027 with net proceeds.
- 90-day lock-up for officers and directors; 75-day lock-up for company on further issuances.
- Placement agent fees: 7% cash fee plus warrants for 5% of shares sold at 125% of offering price.
- Stock price on May 11, 2026: $2.09 per share; 52-week range $1.11 - $5.74.
Financial Impact
~$4.4M gross proceeds; ~$3.94M net; 19% dilution from ~11.3M to ~13.4M shares outstanding (assuming full pre-funded warrant exercise).
Risk Factors
- Immediate 19% dilution to existing shareholders.
- Future dilution from 2.1M purchase warrants exercisable at $2.27 (8% above offering price) starting Nov 2026.
- Going-concern risk; company requires substantial additional funding to continue operations beyond mid-Q1 2027.
- No minimum offering requirement; offering may close with less than full amount, reducing expected proceeds.
- Pre-funded warrants have no public market; limited liquidity for those instruments.
- Stock price volatility; 52-week range $1.11 - $5.74.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-022895 |
| Document: 0001493152-26-022895-index-headers.html | 0001493152-26-022895 |
| Document: 0001493152-26-022895-index.html | 0001493152-26-022895 |
| Document: 0001493152-26-022895.txt | 0001493152-26-022895 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEF 14A | $0.6564 | awaiting T+60 | — | $0.6240 (+4.94%) |
Oct 13, 2026 13d ago | SC 13G/A | $0.7107 | awaiting T+60 | — | $0.6240 (−12.20%) |
Oct 1, 2026 25d ago | 8-K | $0.8601 | awaiting T+60 | — | $0.6240 (+27.45%) |
Sep 30, 2026 26d ago | 8-K | $1.00 | awaiting T+60 | — | $0.6240 (+37.60%) |
Sep 30, 2026 26d ago | 424B5 | $1.01 | awaiting T+60 | — | $0.6240 (+38.22%) |
Sep 23, 2026 4w ago | 8-K | $1.21 | awaiting T+60 | — | $0.6240 (−48.43%) |
Sep 23, 2026 4w ago | 8-K | $1.39 | awaiting T+60 | — | $0.6240 (−55.11%) |
Aug 14, 2026 10w ago | 8-K | $2.65 | awaiting T+60 | — | $0.6240 (−76.45%) |
Jun 22, 2026 18w ago | EFFECT | $3.88 $1.70 | ▲ +56.19% | ▲ +57.93% | $0.6240 (+83.92%) |
May 15, 2026 23w ago | 8-K | $3.00 $2.66 | ▼ −11.33% | ▼ −16.18% | $0.6240 (−79.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers